| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
The primary target is carbonic anhydrase (CA), particularly CA II and CA VB; dichlorphenamide disodium binds the zinc ion in the CA active site and inhibits CO2 hydration, reducing bicarbonate secretion and aqueous humor formation. It shows Ki = 21 nM against human CA VB in stopped-flow CO2 hydration assays, and it is a specific CA inhibitor with oral activity.
|
|---|---|
| ln Vitro |
Dichlorphenamide disodium inhibits carbonic anhydrase with Ki = 21 nM against human CA VB and shows potent inhibition of CA II–mediated CO2 hydration; it reduces aqueous humor secretion in vitro and in vivo, and its CA inhibitory activity translates into lowered intraocular pressure in glaucoma models.
|
| ln Vivo |
In male albino rabbits, disodium dichlorphenamide can locally lower intraocular pressure [1].
In vivo, dichlorphenamide disodium is orally active and effectively reduces intraocular pressure by impeding aqueous humor secretion; it is used for glaucoma and investigated for periodic paralysis, where CA inhibition modulates bicarbonate transport and muscle excitability, with efficacy demonstrated in animal models and clinical studies. |
| Enzyme Assay |
Carbonic anhydrase activity is measured by the stopped-flow CO2 hydration assay: recombinant CA II or CA VB is mixed with CO2-saturated buffer in the presence of a pH indicator (e.g., phenol red) and graded dichlorphenamide concentrations, and the rate of pH change is measured spectrophotometrically; Ki values are calculated from dose–response curves.
|
| Cell Assay |
Aqueous humor secretion is measured in isolated ciliary body preparations or cultured ciliary epithelial cells treated with dichlorphenamide disodium; bicarbonate secretion is quantified by pH-stat or fluorescent pH indicators, CA activity in cell lysates by stopped-flow assay, and cell viability by metabolic assays.
|
| Animal Protocol |
Animal/Disease Models: Male albino rabbit (about 2.5 kg) [1]
Doses: 50 μL 10% dichlorphenamide sodium aqueous solution or 2 mg/kg, 6 mg/kg Route of Administration: 50 μL eye drops or po (oral gavage) 2 mg/kg or 6 mg/kg, 5 hrs (hrs (hours)) Experimental Results: intraocular pressure diminished Dramatically 30 minutes after eye instillation, and intraocular pressure diminished only 1 hour after oral administration. And demonstrated that compared with oral administration, drug levels instilled in the iris-ciliary body were Dramatically higher and drug levels in serum were lower. Rats or rabbits with elevated intraocular pressure receive dichlorphenamide disodium by oral or topical administration at doses selected from pharmacokinetic studies; intraocular pressure is measured by tonometry, aqueous humor flow by fluorophotometry, and plasma and aqueous humor drug concentrations are quantified to correlate CA inhibition with pressure reduction. In periodic paralysis models, muscle excitability and serum potassium are monitored. |
| References |
| Molecular Formula |
C6H6CL2N2NA2O4S2
|
|---|---|
| Molecular Weight |
305.158836841583
|
| Exact Mass |
349.894
|
| CAS # |
76382-13-3
|
| Related CAS # |
Dichlorphenamide;120-97-8
|
| PubChem CID |
131884828
|
| Appearance |
Typically exists as solid at room temperature
|
| tPSA |
137
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
18
|
| Complexity |
452
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=C(C=C(C(=C1S(=O)(=O)N)Cl)Cl)S(=O)(=O)N.[Na].[Na]
|
| InChi Key |
YGKHDOHBVYWFNF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H6Cl2N2O4S2.2Na/c7-4-1-3(15(9,11)12)2-5(6(4)8)16(10,13)14;;/h1-2H,(H2,9,11,12)(H2,10,13,14);;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2770 mL | 16.3848 mL | 32.7697 mL | |
| 5 mM | 0.6554 mL | 3.2770 mL | 6.5539 mL | |
| 10 mM | 0.3277 mL | 1.6385 mL | 3.2770 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.